TRAW תחזית צמיחת רווח נקי למניה לשנה הבאה Traws Pharma Inc

Traws Pharma, Inc. (TRAW) develops convenient oral treatments for respiratory viruses, replacing complex injections with tablets. A robust instrumentation base and contract lines ensure an uninterrupted clinical trial cycle. A strategic alliance with the NIH accelerates the discovery of new molecules and the pursuit of investment. The historical trend of the n+1 profit forecast confirms the asset's potential, and the value has stabilized at -2.90.

Traws Pharma, Inc. (TRAW) development of unique protease inhibitors ensures pricing power, which reflects the current trajectory of next year's EPS forecasts on the GURU.Markets platform. This indicator measures the expected percentage difference between future and current earnings per share, determining the pace of business scaling. Positive dynamics confirm the company's ability to convert innovation into real cash flow even amidst a high cost of capital.